ReviewDrugs2018
Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.
- Use of thiazide diuretics for the prevention of recurrent kidney calculi: a systematic review and meta-analysis.Journal of translational medicine · 2020Pooled it
- Nationwide cohort analysis of pediatric urolithiasis: long-term metabolic, renal, and cardiovascular outcomes.Pediatric nephrology (Berlin, Germany) · 2026Article
- Exposure to topiramate may not increase the risk of urolithiasis: A nationwide cohort study.Epilepsy & behavior reports · 2026Article
- Article
- Nephrolithiasis associated with sulfadiazine therapy in an infant with congenital toxoplasmosis: a case report.BMC pediatrics · 2026Article
- Comparative evaluation of three automated urine sediment analyzers excluding cutoff-related trade-offs.iScience · 2026Article
- Analysis of 33,616 urinary stone cases: novel findings on renal transplantation impact, comorbidity profiles, and composition patterns.Frontiers in immunology · 2026Observational
- Article
- The role of the clinical laboratory in the study of mesalazine-induced nephrolithiasis and crystalluria.Advances in laboratory medicine · 2025Article
- Kidney stone disease: risk factors, pathophysiology and management.Nature reviews. Nephrology · 2025Review
- Associations of genetic proxies for non-steroidal anti-inflammatory drugs with increased kidney stone risk: a Mendelian randomization study.Inflammopharmacology · 2025Article
- Metabolic evaluation of urolithiasis: a narrative review.Urologie (Heidelberg, Germany) · 2025Review
- Single-Cell RNA Sequencing Analysis Reveals the Role of Macrophage-Mediated CD44-AKT-CCL2 Pathways in Renal Tubule Injury during Calcium Oxalate Crystal Formation.Research (Washington, D.C.) · 2025Article
- Association Between the CALLY Index and Kidney Stones: Insights From NHANES 2007-2010.Mediators of inflammation · 2025Article
- A case report of renal oxalosis and secondary hyperoxaluria due to chronic high vitamin C consumption.Clinical nephrology. Case studies · 2025Article
- Drug-induced kidney stones: a real-world pharmacovigilance study using the FDA adverse event reporting system database.Frontiers in pharmacology · 2025Article
- Special Considerations in the Treatment of Idiopathic Intracranial Hypertension.Current neurology and neuroscience reports · 2024Review
- Pediatric Nephrolithiasis: A Changing Landscape Through Time and Space.Medicina (Kaunas, Lithuania) · 2024Review
- The Impact of Stone Composition on Treatment Strategies for Patients with Urolithiasis: A Narrative Review.Cureus · 2024Review
- Successful endourological treatment for a rare case of atazanavir-induced urinary stones.IJU case reports · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced calculi represent 1-2% of all renal calculi. The drugs reported to produce calculi may be divided into two groups. The first one includes poorly soluble drugs with high urine excretion that favour crystallisation in the urine. Among them, drugs used for the treatment of patients with human immunodeficiency, namely atazanavir and other protease inhibitors, and sulphadiazine used for the treatment of cerebral toxoplasmosis, are the most frequent causes. Besides these drugs, about 20 other molecules may induce nephrolithiasis, such as ceftriaxone or ephedrine-containing preparations in subjects receiving high doses or long-term treatment. Calculi analysis by physical methods including infrared spectroscopy or X-ray diffraction is needed to demonstrate the presence of the drug or its metabolites within the calculi. Some drugs may also provoke heavy intra-tubular crystal precipitation causing acute renal failure. Here, the identification of crystalluria or crystals within the kidney tissue in the case of renal biopsy is of major diagnostic value. The second group includes drugs that provoke the formation of urinary calculi as a consequence of their metabolic effects on urinary pH and/or the excretion of calcium, phosphate, oxalate, citrate, uric acid or other purines. Among such metabolically induced calculi are those formed in patients taking uncontrolled calcium/vitamin D supplements, or being treated with carbonic anhydrase inhibitors such as acetazolamide or topiramate. Here, diagnosis relies on a careful clinical inquiry to differentiate between common calculi and metabolically induced calculi, of which the incidence is probably underestimated. Specific patient-dependent risk factors also exist in relation to urine pH, volume of diuresis and other factors, thus providing a basis for preventive or curative measures against stone formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.